Key terms

About ARCT

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ARCT news

Apr 09 7:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Apr 01 7:15am ET Buy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline Progress Mar 26 7:15am ET Optimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in Japan Mar 20 7:30am ET Analysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Alphatec Holdings (ATEC) Mar 20 6:30am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Mar 19 6:12am ET Arcturus Therapeutics’ Kostaive® Vaccine Succeeds in Phase III Mar 11 6:46am ET Arcturus Therapeutics price target raised to $87 from $81 at Canaccord Mar 11 12:40am ET Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT) Mar 08 7:46am ET Arcturus Therapeutics (ARCT) Gets a Buy from Piper Sandler Mar 08 6:59am ET Arcturus Therapeutics price target raised to $58 from $45 at Wells Fargo Mar 08 6:30am ET Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT) Mar 08 5:50am ET Analysts Offer Insights on Healthcare Companies: Cigna (CI) and Arcturus Therapeutics (ARCT) Mar 07 4:03pm ET Arcturus Therapeutics reports Q4 EPS (32c), consensus (99c) Feb 22 8:47am ET EC grants ‘orphan medicinal product designation’ to Arcturus’ ARCT-032 for CF Feb 16 10:31am ET Is Arcturus Therapeutics (NASDAQ: ARCT) the Hidden Gem of Small-Cap Biotech Stocks? Feb 08 6:02am ET Analysts Conflicted on These Healthcare Names: McKesson (MCK), Arcturus Therapeutics (ARCT) and Neurocrine (NBIX) Feb 08 5:51am ET Arcturus Therapeutics price target raised to $48 from $40 at Citi Feb 08 4:55am ET Arcturus Therapeutics management to meet with Piper Sandler Feb 06 4:34pm ET Arcturus Therapeutics management to meet with Piper Sandler Feb 06 9:25am ET Buy Rating on Arcturus Therapeutics Backed by Superior Vaccine Efficacy and Strong Product Pipeline Feb 06 5:40am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 05 8:39am ET Arcturus Therapeutics’ and CSL’s COVID-19 vaccine shows longer immune response Jan 18 11:32am ET Biotech Alert: Searches spiking for these stocks today Jan 15 7:36am ET 3 Best Stocks to Buy Now, 1/15/2024, According to Top Analysts Jan 13 10:15am ET Buy Rating for Arcturus Therapeutics Amid Promising Vaccine Developments and Cost Advantages Jan 10 7:18am ET Piper Sandler Remains a Buy on Arcturus Therapeutics (ARCT)

No recent news articles are available for ARCT

No recent press releases are available for ARCT

ARCT Financials

1-year income & revenue

Key terms

ARCT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ARCT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms